1. Archer T, Fredriksson A (1999) Effects of acute/chronic, subthreshold/threshold doses of L-Dopa in MPTP-treated mice. I. Influence of competitive and noncompetitive NMDA antagonists. In: Palomo T, Beninger R, Archer T (eds) Interactive monoaminergic disorders. Editorial Sintesis, Madrid, pp 573–606
2. Archer T, Bässen M, Peters D, Luthman J, Fredriksson A (1996) Dopaminergicglutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice. In: Beninger R, Palomo T, Archer T (eds) Dopamine disease states. Madrid University Press, Madrid, pp 117–154
3. Björk L, Cornfield LJ, Nelson DL, Hillver SE, Andén NE, Lewander T, Hacksell U (1991) Pharmacology of the novel 5-hydroxytryptaminelA receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther 258: 58–65
4. Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN (1997) Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson’s disease. Neurosci Biobehav Rev 21: 447–453
5. Blomberg LH (1972) Amantadine therapy in parkinsonism. Lakartidningen 69: 5339